Creative Biolabs announced an expansion of its liposomal formulation and encapsulation services aimed at addressing what it calls the 'last-mile problem' in drug delivery. Liposomes, which remain the most successful drug delivery system to date, can effectively solve issues with non-ideal drug properties including low solubility, stability in serum, circulation half-life, biodistribution, and target tissue selectivity.
According to a researcher at Creative Biolabs, liposome research currently faces two common obstacles: selecting appropriate lipids and obtaining sufficient encapsulation efficiency without negatively affecting stability. The company's expanded services directly address these challenges across several major therapeutic classes.
For proteins and peptides, Creative Biolabs focuses on studying the relationship between encapsulation efficiency and phospholipid composition, buffer concentration, incubation time, incubation temperature, and drug loading to provide optimal formulations. This systematic approach aims to maximize therapeutic potential while maintaining stability.
Even traditional small-molecule drugs are pushing the limits of conventional delivery, with many oncology and central nervous system drugs being highly hydrophobic, dose-limited by toxicity, or unable to accumulate in the right tissues. Liposomal encapsulation offers a way to improve solubility, reduce systemic exposure, and fine-tune biodistribution. Creative Biolabs employs two principal methods to encapsulate small molecules within liposomes—passive loading and active loading—each suited to specific types of compounds and applications. The company also provides formulation safety evaluation services that rigorously examine biocompatibility and potential cytotoxicity to ensure formulations meet the highest standards for research use.
As vaccine design becomes more sophisticated, adjuvants must evolve alongside it. Liposomal adjuvants allow developers to integrate immunostimulants—such as MPLA, QS‑21, or TLR agonists—into customizable lipid structures that can shape immune responses with far greater precision. Creative Biolabs offers a complete range of liposome-based adjuvant development services designed to meet the diverse and complex needs of modern vaccine research.
The expansion of these services represents a significant development for pharmaceutical companies and research institutions facing formulation challenges. By addressing the technical hurdles in liposomal delivery, Creative Biolabs aims to accelerate the development of more effective and safer therapeutics across multiple disease areas. The company's comprehensive approach to formulation development could potentially reduce development timelines and improve clinical outcomes for patients. More information about their lipid-based delivery services is available at https://www.creative-biolabs.com/lipid-based-delivery/.
